Weakness in Proteomics and Life Science Research Contributes to Disappointing Q2 for Waters

The firm's revenues were up 14 percent for the quarter but missed Wall Street's estimates due in part to softness in government and academic research and orders delayed in anticipation of the launch of its new Synapt G2-S mass spec.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.